Literature DB >> 12055811

Treatment of Plasmodium falciparum malaria with quinine in children in Guinea-Bissau: one daily dose is sufficient.

Poul-Erik Kofoed1, Fernando Có, Anja Poulsen, Claudina Cabral, Kathryn Hedegaard, Peter Aaby, Lars Rombo.   

Abstract

We have earlier obtained good results in falciparum malaria by treating children with low doses of quinine for 7 days in Guinea-Bissau. In order to further simplify treatment, we compared outcome in 100 children with falciparum malaria treated in 1999/2000 for 7 days with 15 mg quinine salt/kg/dose twice daily (group I), 100 children treated with 7.5 mg quinine salt/kg/dose twice daily (group II), and 100 children treated with one single daily dose of 15 mg/kg. One day 28, parasites had reappeared in 12%, 15%, and 9%, respectively. These results are similar to what has been found after previous successful treatment regimens. Apart from a higher incidence of vomiting during the first 24 h of treatment in the groups treated with 15 mg/kg/dose no significant differences in symptoms or side-effects were found between the groups. In patients suffering from uncomplicated malaria, treatment with quinine can be simplified to one single dose of 15 mg/kg bodyweight whenever logistics make 2 daily doses less feasible.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12055811     DOI: 10.1016/s0035-9203(02)90298-1

Source DB:  PubMed          Journal:  Trans R Soc Trop Med Hyg        ISSN: 0035-9203            Impact factor:   2.184


  2 in total

1.  Dose-dependent resorption of quinine after intrarectal administration to children with moderate Plasmodium falciparum malaria.

Authors:  Eric Pussard; Celine Straczek; Idrissa Kaboré; Auguste Bicaba; Tatiana Balima-Koussoube; Patrice Bouree; Hubert Barennes
Journal:  Antimicrob Agents Chemother       Date:  2004-11       Impact factor: 5.191

2.  Malaria transmission in Bissau, Guinea-Bissau between 1995 and 2012: malaria resurgence did not negatively affect mortality.

Authors:  Johan Ursing; Lars Rombo; Amabelia Rodrigues; Peter Aaby; Poul-Erik Kofoed
Journal:  PLoS One       Date:  2014-07-01       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.